Apogee Therapeutics, Inc. Increase (Decrease) in Accrued Liabilities
Apogee Therapeutics, Inc. (APGE) reported Increase (Decrease) in Accrued Liabilities of $8.79 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-10
- Apogee Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $4.12M.
- Apogee Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was $4.67M, a 77.02% increase year-over-year.
- Apogee Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was -$6.41M.
- Apogee Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $7.74M, a 23.48% decline year-over-year.
- Apogee Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2025 was -$1.07M, a 117.07% decline from fiscal 2024.
- Apogee Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2024 was $6.29M, a 17.79% decline from fiscal 2023.
- Apogee Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2023 was $7.65M.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 5 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 8 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 11 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $8.79M 10-Q · filed 2026-08-10 | $2.37M derived: sum of 3 quarters · filed 2026-08-10 | $10.12M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2026-03-31 | $4.67M 10-Q · filed 2026-05-11 | -$1.74M derived: sum of 2 quarters · filed 2026-05-11 | $6.00M derived: sum of 3 quarters · filed 2026-05-11 | $957.00K derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2025-12-31 | -$6.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $1.33M derived: sum of 2 quarters · filed 2026-03-02 | -$3.71M derived: sum of 3 quarters · filed 2026-08-10 | -$1.07M 10-K · filed 2026-03-02 | |||
| 2025-09-30 | $7.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $2.70M derived: sum of 2 quarters · filed 2026-08-10 | $5.34M 10-Q · filed 2025-11-10 | $1.42M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2025-06-30 | -$5.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$2.41M 10-Q · filed 2026-08-10 | -$6.33M derived: sum of 3 quarters · filed 2026-08-10 | $3.79M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2025-03-31 | $2.64M 10-Q · filed 2026-05-11 | -$1.28M derived: sum of 2 quarters · filed 2026-05-11 | $8.84M derived: sum of 3 quarters · filed 2026-05-11 | $10.68M derived: sum of 4 quarters · filed 2026-05-11 | |||
| 2024-12-31 | -$3.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $6.20M derived: sum of 2 quarters · filed 2026-03-02 | $8.04M derived: sum of 3 quarters · filed 2026-03-02 | $6.29M 10-K · filed 2026-03-02 | |||
| 2024-09-30 | $10.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $11.96M derived: sum of 2 quarters · filed 2025-11-10 | $10.21M 10-Q · filed 2025-11-10 | $11.46M derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2024-06-30 | $1.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $94.00K 10-Q · filed 2025-08-11 | $1.34M derived: sum of 3 quarters · filed 2026-03-02 | $12.23M derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2024-03-31 | -$1.75M 10-Q · filed 2025-05-12 | -$501.00K derived: sum of 2 quarters · filed 2026-03-02 | $10.39M derived: sum of 3 quarters · filed 2026-03-02 | $5.65M derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2023-12-31 | $1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $12.13M derived: sum of 2 quarters · filed 2026-03-02 | $7.39M derived: sum of 3 quarters · filed 2026-03-02 | $7.65M 10-K · filed 2026-03-02 | |||
| 2023-09-30 | $10.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $6.15M derived: sum of 2 quarters · filed 2024-11-12 | $6.41M 10-Q · filed 2024-11-12 | ||||
| 2023-06-30 | -$4.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$4.48M 10-Q · filed 2024-08-12 | |||||
| 2023-03-31 | $261.00K 10-Q · filed 2024-05-13 | ||||||
| 2022-12-31 | $9.56M 10-K · filed 2024-03-05 | ||||||
| 2022-09-30 | $7.67M 10-Q · filed 2023-11-13 | ||||||
| 2022-06-30 | $3.32M 10-Q · filed 2023-08-28 |